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Abstract
Introduction: Rituximab (RTX) therapy of rheumatoid arthritis (RA) exhibits enhanced effectiveness in seropositive
patients. Using patient sera, we tested if this improved efficacy was associated with enhanced RTX mediated
complement-dependent cytotoxicity (RTX-CDC).
Methods: We developed an in vitro assay for RTX-CDC using patient sera and the Daudi human B cell line. Using
propidium iodide uptake and flow cytometry, we compared RTX-CDC with rheumatoid factor (RF)+ sera relative to
normal volunteer, non-RA and RF- sera. Additional studies examined mixing studies of RF+ and RF- sera, as well as
the effect of monoclonal IgA or IgM RF. Finally, the effect of RF on RTX mediated trogocytosis of normal B cells
was evaluated.
Results: Using human sera, addition of RTX resulted in rapid and profound (> 50%) Daudi cell death that was
complement dependent. Surprisingly, RF+ patient sera exhibited reduced RTX-CDC relative to RF- sera, with an
inverse relationship of RTX-CDC and RF titer. Mixing studies indicated the presence of an inhibitor of RTX-CDC in
RF+ sera. The addition of monoclonal IgM or IgA RF to RF- sera markedly inhibited RTX-CDC. This effect was
specific for RF binding to the Fc portion of RTX as it was not apparent with the F(ab)’ domains of RTX engineered
onto IgG3 heavy chain. RF also modestly inhibited RTX mediated trogocytosis.
Conclusions: Contrary to expectations, RF+ sera exhibits reduced RTX-CDC due to the presence of RF. The
enhanced efficacy of RTX in seropositive RA patients cannot be attributed to improved B cell depletion through
CDC. This result indicates that high RF levels may potentially modulate the efficacy of any therapeutic monoclonal
antibody dependent on Fc effector function.
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic inflam-
matory autoimmune disease that is classified as seropo-
sitive or seronegative based on the presence or absence
of the autoantibodies rheumatoid factor (RF) and/or
anti-citrullinated peptide antibodies (ACPA). Whereas
RF is seen in various disease states, ACPA are relatively
specific for RA [1]. These autoantibodies typically
(approximately 95%) coexist and their presence predicts
more erosive disease as well as increased cardiovascular
morbidity in RA patients [2,3]. The nature of this high
degree of coexistence of ACPA and RF remains uncer-
tain. Does the high affinity RF characteristic of RA arise
separately or is it due to the generation of immune
complexes by ACPA? Further questions arise from the
finding that the presence of ACPA and RF predict clini-
cal responses to rituximab therapy in RA [4-6]. The
pathophysiology of each of these associations remains
unclear.
RF activity defines an antibody capable of binding the Fc
portion of IgG in the g2-g3 cleft [7,8]. Interestingly, the
heavy and light chain genes encoding low affinity RF anti-
bodies arise from unmutated germ line immunoglobulin
genes [9]. As a result, B cells capable of producing low affi-
nity IgM RF are detected at a high frequency in the circu-
lation of healthy volunteers [10,11]. The high levels of IgM
RF seen in cryoglobulinemia typically arise from these
germ line immunoglobulin genes [12]. Given their pre-
sence in the germ line and their specificity for the Fc por-
tion of IgG, it has been generally assumed that low affinity
IgM RFs have been evolutionarily selected for roles in
binding and clearing immune complexes (circulating RFs)
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and/or endocytosing IgG containing complexes by RF+ B-
cells so as to stimulate an anti-pathogen response [13,14].
In contrast to RFs seen in healthy controls and
patients with cryoglobulinemia, the RFs associated with
RA are high affinity and frequently have undergone
class switching from IgM to IgA and IgG (reviewed in
[15,16]). For these reasons, it is inferred, but unproven
that these RF-producing plasma cells derived from B
cells that have undergone T cell-dependent affinity
maturation. In fact, it was the high affinity nature of
RA-associated RF that permitted their initial characteri-
zation due to their ability to form immune complexes in
blood in vivo [17]. Subsequent studies have demon-
strated that these RF-containing immune complexes are
also found in the synovial fluid and cartilage of RA
patients [18,19]. Moreover, local RF production has
been demonstrated in RA synovium, so it is likely that
tissue levels of RF are higher than that seen in the circu-
lation [20,21].
Despite these insights, the pathophysiologic role of RF
remains unclear. In a classic in vivo study, administration
of plasma containing high-titer RFs to humans did not
result in articular signs or symptoms [22]. Early labora-
tory studies identified that RF was capable of comple-
ment activation via the classical pathway, suggesting that
RF-immune complexes promote inflammation through
complement activation [23]. Consistent with this con-
cept, levels of RF immune complexes and complement in
synovial fluid are inversely related [18,24]. However, in a
separate study, RF was shown to be very poor at fixing
C4 and C3 [25]. Thus, the precise role of RF in promot-
ing or sustaining complement-induced inflammation is
unclear. Understanding these issues is central to under-
standing the role of RF in RA.
These unresolved issues have taken on greater impor-
tance with the advent of antibody-based therapeutics,
most notably with agents like the anti-CD20 monoclonal
antibody rituximab, where complement-dependent cyto-
toxicity (CDC) might be important for the elimination of
pathogenic B cells (reviewed in [26]). As previously stated,
the presence of seropositivity predicted improved
responses to rituximab (RTX) [4-6]. Thus, we hypothe-
sized that these observations might be linked through the
ability of RF to potentiate B cell depletion by RTX by
enhancing its ability to mediate CDC (RTX-CDC).
We addressed this question using human sera from RA
patients and various controls in an in vitro model of RTX-
CDC. Unexpectedly, a series of findings led us to conclude
that RF inhibits, rather than potentiates, RTX-CDC. RF
does not block RTX binding to the B cell, suggesting that
RF blocks the effector function of its Fc portion. Consis-
tent with this interpretation, we also show that RF inhibits
RTX-mediated trogocytosis, an FcgR-dependent effect
[27,28]. These surprising results relate not only to the con-
sideration of rituximab efficacy in RA, but also illustrate a




Serum-free media X-Vivo 15 and Aim-V were purchased
from Lonza (Walkersville, MD, USA) and Gibco (Life
Technologies, Grand Island, NY, USA), respectively.
Purified human IgG and propidium iodide (PI) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Mouse
anti-human CD45 FITC and mouse anti-human CD20
APC-Cy7 were from BD Biosciences (San Jose, CA, USA)
and mouse anti-human CD19 APC was from BioLegend
(San Diego, CA, USA). Rabbit polyclonal anti-human
C1q FITC was purchased from Abcam (Cambridge, MA,
USA). Rituximab (Genentech, San Francisco, CA, USA)),
a mouse:human chimeric antibody with the human IgG1
heavy chain, and eculizumab (Alexion, Cheshire, CT,
USA), a monoclonal antibody binding complement com-
ponent C5, were obtained from the hospital pharmacy. A
genetically modified form of rituximab engineered to
contain the human IgG3 heavy chain (referred to in the
text as IgG3 RTX) was purchased from InvivoGen (San
Diego, CA, USA). Monoclonal IgM RF was purified from
the ascites from a patient with mixed cryoglobulinemia
as previously reported [29]. Monoclonal IgA RF was a
synthetic molecule with the V-region genes based on the
sequence of RF61 [30] fused to the IgA constant region,
kindly provided by Cayla InvivoGen (Toulouse, France).
Mouse anti-human C3b/iC3b (2H11) was a kind gift
from Ron Taylor (University of Virginia) and was labeled
with Alexa-fluor 488 according to the manufacturer’s
instructions (Life Technologies, Grand Island, NY, USA).
Cells/sera
The Daudi human B cell line was adapted to and main-
tained in the serum-free media X-Vivo 15 in a 5% CO2
incubator at 37°C. Healthy donor and patient sera were
obtained following written consent to a protocol approved
by the Committee for the Protection of Human Subjects at
Dartmouth College. Blood was drawn into sterile glass
tubes, allowed to clot and the clot pelleted by 15-minute
centrifugation (700 g). Sera was aspirated, aliquotted and
frozen at -80°C until shortly before use. Sera were obtained
from healthy donors (n = 15), non-RA patients (n = 15),
seronegative RA patients (n = 15), and seropositive RA
patients (n = 40). All seropositive and seronegative RA
patients had established disease for more than two years.
Non-RA patients included four patients with osteoarthri-
tis, psoriatic arthritis, with vasculitis/polymyalgia rheuma-
tica (PMR), two with an undifferentiated seronegative
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inflammatory arthritis, and one with arthropathy asso-
ciated with celiac disease.
Blood was obtained from healthy volunteer donors fol-
lowing informed consent and peripheral blood mononuc-
lear cells (PBMC) purified by discontinuous gradient
isolation using Ficoll-Paque PLUS (GE Healthcare Bios-
ciences, Uppsala, Sweden). B cells were isolated by nega-
tive selection, using Invitrogen’s Untouched B-Cell
Isolation Kit (#113.51d, Life Technologies, Grand Island,
NY, USA). CD20 density on cell surfaces was determined
by pelleting healthy PBMC and Daudi cells, staining with
anti-CD20 APC-Cy7 on ice for 30 minutes, fixation with
1% formaldehyde, followed by CD20 mean fluorescent
intensity (MFI) measurement using MACSQuant Analy-
zer (Miltenyi Biotec, Boston, MA, USA), and interpreta-
tion using FlowJo software (TreeStar, Ashland, OR,
USA).
Rheumatoid factor status
Seropositivity was determined by chart review for indivi-
dual patient sera and typically reflected that obtained by
nephelometry. Seropositivity for IgM RF and IgA RF was
confirmed and quantified using an ELISA (TheraTest,
Lombard, IL, USA). Three donors who were originally
classified as seronegative RA by chart review yielded low
levels of RTX-CDC and were subsequently confirmed to
have IgA and IgM RF by ELISA, and were re-classified as
seropositive for the purposes of this study.
Rituximab complement-dependent cytotoxicity (RTX-CDC)
assay
RTX (0.1 to 10 μg/ml) was added to Daudi cells in X-Vivo
15, followed by immediate addition of human serum (1, 2
or 5%) in round bottom flow cytometry tubes (BD Falcon,
BD Biosciences, San Jose, CA, USA), at a final concentra-
tion of 250,000 cells/ml, incubated for 30 minutes at either
RT or 37°C followed by addition of propidium iodide (PI-1
μg/ml final concentration). Flow cytometry was utilized
to determine dead cells by PI uptake (FACScan, BD
Biosciences, San Jose, CA, USA) after a 30-minute incuba-
tion. Complement-independent effects on Daudi cell viabi-
lity were assayed using RTX in serum-free X-Vivo
15 alone, with 5% C5 deficient serum (Sigma-Aldrich, St.
Louis, MO, USA), or 5% heat-inactivated serum (56°C for
45 minutes), compared to 5% normal human serum and
assayed as described above.
Inhibition of RTX-CDC by rheumatoid factor
Mixing studies were performed using seronegative serum
with RF positive serum, each at 1% of total volume, prior
to addition of RTX. Similarly, monoclonal IgM or IgA RF
was added to 1% serum prior to addition of RTX and then
Daudi cells. Assessment of Daudi cell viability was per-
formed as above.
RTX blocks C3b and C1q deposition on B cells
Highly enriched human B cells (approximately 97% puri-
fied) obtained from healthy donors were cultured at a
concentration of 1 × 106 cells/ml in RPMI + 10% normal
human serum with RTX at 0.1, 1, and 10 μg/ml in the
presence or absence of 10 μg/ml monoclonal IgM RF at
RT for 30 minutes, followed by a wash with ice cold PBS/
BSA/Azide. After pelleting, the cells were stained with
Al-488 labeled anti-C3b/iC3b antibody for 30 minutes on
ice, washed and then fixed with 1% paraformaldehyde.
C3b deposition on cells was determined by flow cytome-
try using FACSCalibur (BD Biosciences, San Jose, CA,
USA).
Daudi cells were subjected to the standard RTX-CDC
assay as outlined above, using either healthy donor serum
or RF+ serum. Prior to addition of RTX, half of the cells
were incubated with eculizumab 10 μg/ml, a C5 inhibitor,
for 15 minutes, to prevent CDC but to still allow for C1q
fixation. After a 30-minute incubation at RT, the cells
were washed with ice cold PBS/BSA/Azide, pelleted and
stained with FITC labeled rabbit polyclonal anti-human
C1q antibody for 30 minutes on ice. After another wash,
the cells were fixed with 1% paraformaldehyde and C1q
deposition was determined by flow cytometry using
FACSCalibur.
RF binds to RTX after cell attachment to inhibit CDC
To discriminate the mechanism by which RF blocked
RTX-CDC, the effect of preincubating (15 minutes) Daudi
cells with RTX (10 μg/ml) to bind cell surface CD20 prior
to the addition of 1% serum and IgM RF 50 μg/ml was
compared with combining RTX, IgM RF and serum prior
to adding Daudi cells. Cell viability was measured as
described above. Similarly, the effect of RF on RTX
engagement of CD20 was measured by incubating Daudi
cells with RTX 10 μg/ml alone, IgM RF 50 μg/ml alone, or
a combination of RTX and IgM RF for 30 minutes fol-
lowed by staining with mouse anti-human CD20 APC-
Cy7 and evaluated by flow cytometry (FACSCanto, BD
Biosciences, San Jose, CA, USA).
IgM RF blocks IgG1 effector function, but not IgG3
As a comparison to standard RTX (IgG1), IgG3 RTX
(InvivoGen) was used in the RTX-CDC assay. RF positive
sera were used in parallel with RF negative sera at 2% of
total volume. Alternatively, 2% RF- sera was utilized in
the RTX-CDC assay with or without the addition of 50
μg/ml monoclonal IgM RF. Due to limited quantities of
IgG3 RTX, a concentration of 1 μg/ml was utilized
instead of 10 μg/ml.
Effect of RF on RTX trogocytosis
Blood, obtained from healthy volunteer donors following
informed consent, and PBMC, purified by discontinuous
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gradient isolation using Ficoll-Paque PLUS (GE Health-
care Biosciences), were resuspended in Aim V serum-free
media (Gibco) at 2 million cells/ml. PBMC were then
combined with no RF, 10 μg/ml IgM or IgA RF, or 100
μg/ml IgM or IgA RF. The PBMC were either untreated,
or were treated with RTX 10 μg/ml for 30 minutes at RT.
The cells were then washed in cold PBS/BSA/Azide, pel-
leted, then stained with anti-CD19 APC and anti-CD45
FITC for 30 minutes on ice. After another wash, the cells
were pelleted and fixed with 1% paraformaldehyde, fol-
lowed by flow cytometry using FACSCalibur.
Statistics
Statistical analysis was performed using STATA software
(StataCorp, College Station, TX, USA). Error bars repre-
sent standard error of the mean. Statistical significance of
IgM and IgA RF concentration to degree of CDC was
determined using linear regression. Where appropriate,
comparison of two means was performed using the t-test,
with a P < 0.05 considered statistically significant.
Results
Development of a RTX-CDC assay
RTX mediates B cell depletion through various mechan-
isms, including CDC [26]. To test the hypothesis that RF
might enhance RTX-CDC, we developed an in vitro assay
with the human Daudi B cell line and human sera. Since
determining that cell viability is the best measure of CDC
[31], we used propidium iodide (PI) uptake to determine
the amount of RTX-CDC present. There were no differ-
ences in RTX-CDC assay performed at RT and at 37°C,
so subsequent experiments were performed at RT (n = 6,
data not shown). Under these conditions, RTX (10
μg/ml) mediated rapid (minutes) and significant cell
death (40%) with only 1% normal human serum (n = 3,
Figure 1A). Nearly complete cell death (88%) was
observed with 5% serum. Dose titrations of RTX in the
presence of 2% and 5% serum showed cell death of 23%
and 78%, respectively, at 1 μg/ml (n = 3, Figure 1B). This
difference between 2% and 5% narrowed to 73% and 98%
cell death using RTX at 10 μg/ml. All observed Daudi
cell death was complement-dependent; there was none
seen using RTX (10 μg/ml) with serum free media, heat-
inactivated serum (56°C, 45 minutes), or C5 deficient
serum (Figure 1C).
Disease-associated variations in RTX-CDC
We hypothesized that the presence of RF in human sera
would enhance RTX-CDC. To investigate this, we mea-
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Figure 1 RTX complement-dependent cytotoxicity (CDC) induced death of Daudi human cell line. A. Effect of varying concentration of
normal human serum (NHS) with RTX 10 μg/ml (n = 3) as determined by propidium iodide staining. B. Effect of varying RTX concentration with
2% and 5% NHS (n = 3). Error bars represent mean standard error. C. Daudi cell death with 5% NHS represents CDC as evidenced by lack of cell
death in complement free conditions (serum free media, C5 deficient serum, and heat inactivated (HI) serum).
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populations: healthy donors (n = 15), non-RA patients
(n = 15), seronegative RA patients (n = 15), and seropo-
sitive RA patients (n = 40). Using limiting serum con-
centrations (1%), the average cell death in sera from
healthy donors and seropositive RA donors was very
similar (54% and 47%, respectively, P = 0.28) (Figure 2A),
though greater variability was seen using sera from sero-
positive patients. Interestingly, the RTX-CDC seen with
non-RA patients and seronegative RA patients was signif-
icantly higher (P < 0.0001). While it was not surprising
that sera from patients with systemic inflammation had
higher RTX-CDC than healthy donors, the reduction in
RTX-CDC and the wide variability of RTX-CDC seen
with sera from seropositive RA patients was completely
unexpected. This apparent incongruity became clear
upon finding that stratification of RTX-CDC as a func-
tion of RF titer clearly showed an inverse correlation
(Figure 2B-D). The correlation held true with IgA RF (R2
= 0.18; P < 0.006), but was stronger for IgM RF (R2 =
0.45; P < 0.0001) (Figure 3).
Seropositive sera inhibits CDC when mixed with
seronegative sera
One possible mechanism for this observation was the pos-
sible association of RF titer with reductions in serum com-
plement. If true, a mixing study with normal human serum
would be expected to correct the reduction in RTX-CDC.
The mixing of 1% serum from a seropositive patient with
those from seronegative patients showed the opposite
result: RF+ sera inhibited RTX-CDC (n = 3, Figure 4A).
Thus, the decreased RTX-CDC associated with RF+ sera
operated in trans to block RTX-CDC.
Rheumatoid factor inhibits RTX-CDC
These data indicated the presence of an inhibitor in RF+
sera. The potential role of RF itself binding to the Fc
portion of rituximab was supported by finding that a
monoclonal IgM RF markedly reduced RTX-CDC (n =
3), becoming maximal at 50 μg/ml (Figure 4B). A similar































































Figure 2 RTX-CDC varies as a function of patient sera and correlates with RF levels. A. RTX-CDC using Daudi cell line with 1% human sera
stratified by disease state: healthy donors, non-RA disease, seronegative RA (RF-), and seropositive RA (RF+). Data represent the mean cell death
obtained with 15 sera in each category except for RF+ (n = 40). B, C, D. RTX-CDC cell death declines with increasing titer of RF, with a stronger
correlation with IgM RF. Error bars represent mean standard error.
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Rheumatoid factor blocks C3b deposition on normal B
cells and C1q deposition on Daudi cells
Normal human B cells were used as an alternative
model to study the role of RF on rituximab function.
We have previously shown that, in contrast to the
Daudi lymphoblastoid cell line, human peripheral blood
cells B cells are resistant to RTX-CDC [27]. The nature
of this resistance is unclear; Daudi cells express higher
levels (20×) of surface CD20 (data not shown), but are
also much larger. Thus, instead of measuring cell death
to assess modulation of rituximab activity by RF, we
measured deposition of C3b on the B cell surface. Using
highly enriched B cells (approximately 97% purified),
RTX was added in the presence or absence of monoclo-
nal IgM RF, followed by measurement of C3b deposition
by flow cytometry (n = 5). These studies revealed that
RF inhibited RTX dependent C3b deposition (Figure 5A).
To confirm the hypothesis that RF blocks CDC by limit-
ing C1q binding to RTX-CD20 complexes, Daudi cells
were combined with RTX and sera from healthy donors or
RF+ donors, followed by measurement of C1q deposition
by flow cytometry. Figure 5B illustrates that RF+ sera
resulted in a nearly 50% inhibition of C1q binding (n = 3,
P < 0.05), which was unaffected by eculizumab.
Rheumatoid factor blocks complement fixation of RTX
after RTX engagement of CD20 on the cell surface
The effect of RF on RTX-CDC (and C1q deposition)

































Figure 3 Dot-plots of RTX-CDC of Daudi cells as a function of RF
concentration (IU/ml). Using RTX 10 μg/ml and 1% serum, CDC was
determined as a function of A. IgM RF concentration (n = 40, R2 = 0.45,
















































Figure 4 Inhibition of RTX-CDC is mediated by RF. A. Mixing
studies using seronegative (RF-) and seropositive (RF+) sera
demonstrates inhibition of CDC by RF+ sera, indicating that an
inhibitor, not a factor deficiency, decreases CDC. B. Addition of
monoclonal IgM RF markedly inhibits RTX-CDC by NHS. C. Addition
of monoclonal IgA RF markedly inhibits RTX-CDC by NHS. Graphs
represent average of three experiments; error bars represent mean
standard error.
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preventing binding to CD20 on the B cell. Alternatively,
RF engagement of the Fc domain of RTX might block the
recruitment of complement after RTX had engaged with
CD20. To investigate these possibilities, we compared the
resultant CDC from preincubation (15 minutes) of Daudi
cells with RTX (to ensure B cell binding) followed by addi-
tion of IgM RF and serum relative to the simultaneous
addition of RTX, RF and serum (Figure 6A). RF blocked
RTX-CDC independent of the time of addition (stepwise
vs. simultaneous) (n = 3, P = 0.34). These data suggest
that RF inhibits complement binding to the Fc portion of
RTX after it has bound CD20. This interpretation was
supported by the observation that RF had no effect on
RTX binding to CD20, as measured by the lack of modula-
tion of the ability of RTX to block the binding of fluoro-
chrome-labeled anti-human CD20 (APC-Cy7) to Daudi
cells (Figure 6B). Thus, RF does not limit the ability of
RTX to bind CD20 on the B cell. These data suggest that
RF inhibits C3b deposition and cytotoxicity by preventing
C1q binding to the Fc portion of RTX.
Rheumatoid factor inhibits IgG effector function through
binding the Fc portion of RTX
IgM RF reacts with the cleft in the Cg2/Cg3 Fc portion
of human IgG1, IgG2 and IgG4, but not IgG3 [7,8]. To









































Figure 5 Rheumatoid factor blocks C1q and C3b deposition. A. Enriched normal human B cells were treated with RTX at varying
concentrations in the presence or absence of IgM RF 10 μg/ml for 30 minutes, and then stained for C3b (n = 5). B. Daudi cells were treated
with RTX 10 μg/ml for 30 minutes in the presence of healthy serum or RF+ serum, with or without eculizumab 10 μg/ml, followed by staining
for C1q (n = 3). Mean fluorescence intensity (MFI) was determined by flow cytometry. Error bars represent mean standard error.
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a specific Fc domain, we compared RTX-CDC relative
to IgG3 RTX. IgG3 RTX differs from RTX only in the
presence of an IgG3 instead of IgG1 heavy chain. IgG3
RTX mediated RTX-CDC more efficiently than IgG1
RTX. More importantly, the addition of monoclonal
IgM RF to RF- sera (n = 3) inhibited CDC with IgG1
RTX, but not with IgG3 RTX (Figure 7A).
To further confirm that RF modulates the ability of the
Fc portion of RTX to mediate effector function, we evalu-
ated an alternate activity (trogocytosis) of the Fc portion
of RTX using normal human B cells. Rituximab binds the
surface of normal human B cells and mediates loss of
CD19 and CD20 through engagement of the Fc portion
of RTX by effector cells expressing FcgR [27,28]. This
process is complement-independent and not associated
with cell death [27]. We examined trogocytosis with RTX
using PBMC from healthy donors, measuring the degree
of CD19 loss by flow cytometry in the absence or pre-
sence of RF. Both IgM (n = 6) and IgA RF (n = 3) inhib-
ited CD19 loss by trogocytosis to a moderate degree
(Figure 7B).
Discussion
We report the unexpected result that RF inhibits the
ability of RTX to mediate CDC of human B cells. This
effect is not associated with decreased RTX binding to
CD20 on B cells, suggesting that RF sterically inhibits
the ability of the Fc domain of RTX to bind and/or
recruit the proximal components of the complement
cascade, namely C1q [32]. To a lesser degree, RF addi-
tionally blocks the ability of RTX to mediate ‘shaving’ or
trogocytosis of CD19, an Fc-dependent process [27,28].
The requirement for RF binding to the Cg2/Cg3 cleft in
IgG1, IgG2 and IgG4 for this inhibition was confirmed
by the lack of effect of RF on CDC by a variant of RTX
containing the IgG3 heavy chain [7].
This effect on RTX-CDC was seen with both mono-
clonal IgM and IgA RF and exceeded their effect on tro-
gocytosis. This observation corresponds to the relative
distance of these effector domains (C1q binds Cg2; FcgR
binds the upper Cg2 + hinge regions) from the RF bind-
ing site in the Cg2/Cg3 cleft [32-35]. Thus, steric hin-
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Figure 6 IgM rheumatoid factor does not prevent RTX attachment to CD20. A. RF inhibits B cell death whether RTX is first added to cells
followed later by RF addition (Stepwise), or if RTX and RF are added simultaneously (n = 3). Error bars represent mean standard error. B.
Representative data (n = 2) showing that RTX blocks binding of anti-human CD20 APC-Cy7, and addition of RF to RTX does not lessen this
blocking outcome.
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observation that IgA RF appeared more effective than
IgM RF at decreasing RTX-CDC, but not trogocytosis,
is potentially interesting and suggests additional interac-
tions that require further study.
Clinical trials indicate that rituximab exhibits superior
efficacy in the treatment of seropositive RA relative to
its seronegative counterpart, particularly in the presence of
IgA RF [4]. Based on animal models of rituximab action,
we postulated that RTX-CDC would be required for the
depletion of non-circulating pathogenic synovial B cells
[36]. In this model, we expected that local production of
RF in synovium might potentiate RTX-CDC. However,
our results show the opposite effect, RF inhibits RTX-
CDC. These results enhance our understanding of the
mechanism of action of RTX in vivo, in that they suggest
that RTX-CDC does not account for the increased efficacy
of RTX in seropositive patients. The potential impact of
C3a and C5a generation through complement fixation by
RTX was not specifically measured.
In contrast, we also demonstrated that RF decreased the
ability of phagocytic cells to mediate ‘shaving’ or trogocy-
tosis of CD19 from normal human B cells, which is an
FcgR-dependent process. Thus, the presence of RF might
prevent the loss of the CD20-RTX complex by trogocyto-
sis, enabling enhanced levels of B cell depletion by anti-
body dependent cellular cytotoxicity (ADCC) to occur.
However, this activity of RF would also be predicted to
block ADCC, although it is possible that ADCC and tro-
gocytosis might be differentially modulated by RF binding.
Finally, our studies may underestimate the magnitude of
the effect of RF in an inflamed joint given its high concen-
trations that arise from local production [20,21].
These findings suggest a need for a more general re-
examination of RF biology, as the literature is unclear on
this topic. Animal models have shown that RF promotes
immune complex clearance presumably through the for-
mation of larger complexes and fixation of proximal com-
ponents of the complement cascade [37,38]. Moreover,
clinical samples have shown lower levels of complement
(C3 and CH50) in association with higher levels of RF and
immune complexes [18]. However, direct measures indi-
cate that IgM RF is poor at fixing complement [25]. Our
findings are consistent with this latter finding and prompt
us to ask: If RF blocks effector function in terms of C1q
and FcgR binding, how are these activities reconciled with
its ability to enhance immune complex clearance?
Conclusions
We report the surprising finding that RF inhibits several
RTX effector functions (complement dependent cytoxicity,
FcR-mediated trogocytosis of CD19). These effects are
attributable to the ability of RF to bind to the Cg2/Cg3
cleft of the Fc portion of rituximab and sterically inhibit
both C1q binding and FcgR engagement. These data sug-
gest a surprising paradox as they are the opposite results
that one would predict given the superior efficacy in sero-
positive RA. However, the implications of this binding
potentially extend beyond rituximab to any antibody-
based therapeutic in RA, particularly those in which Fc-
dependent function is important for clinical benefit.
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Figure 7 RF inhibits rituximab effects by binding the Fc portion of RTX. A. Monoclonal IgM RF has an inhibitory effect on RTX-CDC when
RTX (1 μg/ml) has an IgG1 heavy chain, but not when RTX has an IgG3 heavy chain (n = 3). B. Addition of RTX 10 μg/ml to PBMC in serum free
media after addition of monoclonal IgM RF (n = 6) or IgA RF (n = 3) inhibits loss of CD19 by RTX-mediated trogocytosis. Inhibitory effects of RF
found to be statistically significant (P < 0.05) are indicated by asterisks. Error bars represent mean standard error.
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